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Abstract Dual Orexin Receptor Antagonists (DORA) bind
to both the Orexin 1 and 2 receptors. High resolution crystal
structures of the Orexin 1 and 2 receptors, both class A
GPCRs, were not available at the time of this study, and thus,
ligand-based analyses were invoked and successfully applied
to the design of DORAs. Computational analysis, ligand based
superposition, unbound small-molecule X-ray crystal struc-
tures and NMR analysis were utilized to understand the con-
formational preferences of key DORAs and excellent
agreement between these orthogonal approaches was seen in
the majority of compounds examined. The predominantly
face-to-face (F2F) interaction observed between the distal
aromatic rings was the core 3D shape motif in our design
principle and was used in the development of compounds. A
notable exception, however, was seen between computation
and experiment for suvorexant where the molecule exhibits an
extended conformation in the unbound small-molecule X-ray
structure. Even taking into account solvation effects explicitly
in our calculations, we nevertheless find support that the F2F
conformation is the bioactive conformation. Using a dominant
states approximation for the partition function, we made a
comprehensive assessment of the free energies required to
adopt both an extended and a F2F conformation of a number of
DORAs. Interestingly, we find that only a F2F conformation is
consistent with the activities reported.
Keywords Suvorexant  Conformational analysis 
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Introduction
Orexins, or hypocretins, are neuropeptide hormones that have
been shown to regulate arousal and wakefulness [1]. There
remains debate in the scientific community as to whether these
neuropeptides should be referred to as orexins or as hypo-
cretins after being simultaneously discovered by two inde-
pendent research groups [2, 3]. The term orexin originates
from the Greek word, orexis, which means appetite, while
hypocretin is derived from the observation that it is secreted in
the lateral hypothalamus and is similar to the hormone
secretin. Herein, we will refer to the neuropeptides as orexins
and the compounds that antagonize both the Orexin 1 and 2
receptors (OX1R and OX2R, respectively) as Dual Orexin
Receptor Antagonists, or DORAs.
Orexinergic neurons project to different areas in the
central nervous system, which include areas of the brain
that regulate the sleep-wake cycle, and there is strong
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genetic and pharmacological evidence implicating the role
of orexins in sleep-wake regulation. Indeed, blockade of
orexin signaling by small-molecule antagonists has been
shown to promote sleep in preclinical species and in human
clinical trials [4].
In previous publications from this laboratory we
described the development of numerous chemotypes (dia-
zepanes, tetrahydroisoquinolines, diazaspirodecanses and
proline amides) arising from a successful high-throughput
screening campaign [5]. For the purposes of this manu-
script, we focused only on the diazepane ring structures.
We will describe the 3D shape motif, conformational
analysis, and X-ray structure of suvorexant.
Discovery and exploitation of core 3D shape motif
As previously described [6], a strong correlation between
the predicted bioactive conformation of compound 1
(Fig. 1) and experimental methods was established.
Initially, we used the mixed torsion/low-mode sampling
algorithm implemented in Maestro [7]1 with the OPLS
2005 force field in the gas phase which suggested a folded,
face-to-face (F2F) conformation wherein distal ring sys-
tems pack against each other as depicted in Fig. 1. Given
that dispersion forces can sometimes be too large in force-
fields which might lead to a bias towards F2F conforma-
tions, we invoked additional computational methods (e.g.
quantum mechanical), included solvent to aid or refute the
effects of hydrophobic collapse and experimented with
using different force fields (Table 1).
The results of this study demonstrated that there was
excellent agreement between the molecular mechanics
force fields, MMFFs and OPLS and the use of solvent did
not affect the predominant conformation. The use of sol-
vent in the quantum mechanical calculations was not
required to achieve the F2F conformation as the hypothe-
sized bioactive conformation. All reported conformations
were minimized to convergence [7].
Although the molecular and quantum mechanical meth-
ods were in agreement with one another, we sought addi-
tional experimental methods to either support or refute our
initial computational findings. We first determined the
unbound, small-molecule crystal structure. The RMSD
between the computationally derived conformation depicted
in Fig. 1 and the X-ray structure was 0.75 A˚ (non-hydrogen
atoms). Additionally, no differences between the geometries
of the nitrogen atoms of the seven-membered ring nor the
amide bond were observed between the theoretically and
experimentally derived conformations. Even though there
was no computed difference between the conformations
(Table 1) when implicit solvent was invoked, we sought to
experimentally confirm that the solution state conformation
was consistent with the aforementioned theoretical and
crystal structure experiments. There was again excellent
agreement from NMR spectroscopy applied to compound 1,
with NOE evidence for the F2F interaction in the major
rotamer. In fact, two F2F rotamers in the ensemble accounted
for 82 % of the total solution conformation (CD3OD at
-40 C), each with a motif similar to that found by com-
putational analysis and X-ray structure.
We were encouraged that the solid-state, solution and
theoretical data all correlated and so further tested the
importance of the F2F interaction through synthetic design.
If the F2F motif was the predominant active conformation,
then we hypothesized that a macrocyclic structure which
forced such a motif to exist should be at least equally
active, within experimental error. Indeed, as was previ-
ously published, this hypothesis was confirmed [6]. As
predicted, the OX1R and OX2R binding values of the
synthetic precursor and macrocycle DORAs were within
experimental error (Table 2).
We were confident at this juncture that the 3D motif was
reflective of the bioactive conformation. We had (1) two
experimental methods (unbound small-molecule X-ray and
NMR) corroborating our conformational analysis and (2)
similar biological results attained from both the acyclic and
macrocycle compounds. Thus, the F2F interaction became
an important criteria adopted in our synthetic work, and we
analyzed compounds based on whether they could attain
this unique 3D shape motif.
Quantification of F2F using ROCS
Even though the orexin 1 and 2 targets were known and we
did generate homology models of the receptors, we found the
ligand based drug design approach to be more successful. We
Fig. 1 2D and 3D small molecule low energy, computationally-
derived representation of Compound 1 (OX1R Ki = 1.2 nM, OX2R
Ki = 0.8 nM. Individual replicates for all data shown herein are
included in the supplementary material. Only the mean is reported
1 Conformational searching using the mixed torsion/low-mode sam-
pling algorithm as implemented in Schro¨dinger, v9.0 (Schro¨dinger,
LLC, v9.0) was utilized with default values. It was found that the
number of maximum iterations using the PRCG method needed to be
increased to 5,000 for convergence to occur.
6 J Comput Aided Mol Des (2014) 28:5–12
123
used a combination of Merck’s proprietary method, SQW [8]
and OpenEye’s method ROCS [9], both 3D shape methods,
to rank order the ability of compounds 4–7 [10, 11] to con-
form to our proposed bioactive form, the F2F motif. Both
these tools are ligand shape-based methods and we utilized
them to analyze compounds. For this manuscript, however,
we will report the ROCS Tanimoto Combo Score values as
they can be independently reproduced.
Once we had experimental confirmation that compound
1 did indeed adopt a F2F conformation, we used the small-
molecule X-ray conformation as our reference and calcu-
lated: (1) the low energy conformations using a combina-
tion of the MMFFs and/or OPLS force field [7], and (2) the
Tanimoto Combo score (a sum of shape and 3D chemical
Tanimoto values) as implemented in ROCS (Table 3), [9].
Initially, we generated conformations as previously pub-
lished [6] but as we progressed into lead optimization, we
expanded our conformational sampling by using OMEGA
and increased the energy range and number of conforma-
tions to ensure larger conformational sampling [12]. Thus,
the Tanimoto Combo scores reported in Table 3 are a result
from assessing large ensembles of conformations ([100)
and reporting the best (highest) Tanimoto Combo score.
As expected, compound 1 exhibited a high Tanimoto
Combo score since it was calculated relative to itself, thus
tests our facilities to computationally find this presumably
low energy conformation. As can be seen in Table 3, all
compounds except compound 5 exhibit ROCS Tanimoto
Combo scores suggested of activity based on a publication
by Muchmore et al. [13]. In contrast, compound 5 has a
lower ROCS Tanimoto Combo score giving us further
confidence that the F2F shape motif discriminates between
actives and in-actives. Compound 4 exhibits a ROCS
Tanimoto Combo score in the low predicted activity range;
however, it is still higher relative to Compound 5.
It is known that ROCS can in some cases, overcom-
pensate for initial overlaps based on the chemical nature of
existing rings in the ligands. The score for compound 5 is
such that the Muchmore scale would not have anticipated
activity. We wondered, however, if the reason compound 4
Table 1 Effect of solvent and level of theory on the predominant
conformation of compound 1
Compound 1 F2Fa Extendeda
OPLS 2005 gas 0.0 2.7
OPLS 2005 solvent 0.0 1.1
OPLS gas 2.1 0.0 3.6
OPLS water 2.1 0.0 2.7
MMFFs gas 0.0 1.1
MMFFs solvent 0.0 2.1
RHF/6-31G** gas 0.0 1.4
RHF/6-31G** PBF 0.0 2.9
a All values reported in kcal/mol and the minimum value is nor-
malized to zero
Table 2 An acyclic (compound 2) and cyclic (compound 3) structure was synthesized and tested in both the Orexin 1 and Orexin 2 receptor
binding assay






Table 3 ECFP4 and Tanimoto scores relative to the 2D and crystal
structure of compound 1











1 1.2 0.8 1.000 1.722 1.575
4 0.4 0.6 0.727 1.146 1.242
5 [1,700 2740 0.717 0.928 0.955
6 0.6 0.2 0.731 1.618 1.499
7* 0.54 0.35 0.667 1.622 1.587
* Compound 7 is also known as MK-4305 or Suvorexant
a OX1R and OX2R Ki values are reported as nM
b ECFP4 and Tanimoto scores of each compound relative to the small
molecule X-ray structure of compound 1
J Comput Aided Mol Des (2014) 28:5–12 7
123
was not more highly ranked was the default behavior of the
ROCS scoring function towards rings, i.e. whether the
bridged rings in compound 4 and 5 were not being
‘rewarded’. The last column in Table 3, wherein we use the
‘‘No Rings’’ version of the ROCS overlap function, sug-
gests this was indeed the case. In general scores are
expected to be lower and were, however compound 4, and
compound 5 to a lesser degree, improved. Compound 5
would still be classified as likely inactive, whereas all the
other compounds, including now compound 4, would be
solidly classified as likely active.
We did attempt to correlate strain energy to biological
activity but did not find this a good metric for distin-
guishing actives from inactives as the accessible confor-
mations were all relatively low strain. These strain energy
calculations did not take into account entropy. It is
worthwhile to note that the topological method, ECFP4
[14], was not able to distinguish actives from inactives and
further underscore the importance of using 3D shape in this
study.
We analyzed compounds 4–7 using the ROCS and SQW
methodologies which are designed to virtually screen
molecules based on shape. In the case of compound 4, both
X-ray and NMR structures could be determined and it was
established that indeed, the F2F conformation was pre-
dominant (Fig. 2). In contrast, compound 5 was shown by
conformational analysis to not present itself in the F2F
conformation and turned out to be[1,000 times less active
than compound 4. The lack of predicted F2F activity was
supported experimentally by the absence of observed NOE
correlations between the distal aromatic rings. Compound 6
was predicted to present the distal aromatic rings in a F2F
arrangement and this was experimentally observed in the
small-molecule X-ray structure. In all three cases (com-
pounds 4–6), the computational analysis was supported by
experimental methods and by a biological binding assay.
These results are summarized in Fig. 2.
Compound 6 demonstrated excellent in vivo activity but
was subsequently found to exhibit a metabolic liability
[10]. A 6,5 heterocycle, the benzoxazole, was unexpectedly
found to be a replacement for the quinazoline ring that is
devoid of the metabolic issues in compound 6 (compound
7, Fig. 3) [15]. Since the only change was the bicyclic
heterocycle, the ROCS Tanimoto Combo Score for Com-
pound 7 of 1.622 was similar to that of compound 6
(1.618). Compound 7 was studied in vivo and shown to
promote sleep in preclinical species in a dose dependent
Fig. 2 2D representation of
chemical structures and
corresponding 3D low energy
conformation of ligands
Fig. 3 2D representation of compound 7 which became our clinical
candidate (MK-4305) and later termed Suvorexant (OX1R Ki = 0.54
nM, OX2R Ki = 0.35 nM)
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fashion and also demonstrated a favorable toxicology
profile.
Further analysis concluded that compound 7 was highly
selective for orexin receptor binding and the compound was
CNS penetrant with a rat brain/plasma ratio of 0.6–1.2 in an
iv infusion study. Compound 7 (MK-4305) was advanced as
a clinical candidate and was termed suvorexant.
Is the 3D motif ‘‘true’’?
In parallel to our back-up efforts, suvorexant continued to
progress through all phases of clinical trials (currently in
Phase III). As part of this process we obtained an unbound
small molecule crystal structure of suvorexant and were
surprised to observe that the molecule adopts an extended
conformation crystallographically, not the predicted F2F
arrangement (Fig. 4). Our first reaction was to postulate
that perhaps one of the amines on the ligand could be
protonated and that may have altered the ability to adopt a
F2F conformation. We subsequently grew crystals from a
supersaturated (55 C) ethyl acetate solution to test this
hypothesis. This second X-ray structure still exhibited an
extended conformation. Our next option was to apply NMR
spectroscopy since we had previously shown a strong
correlation between these methods (i.e. computational
chemistry, X-ray crystallography and NMR spectroscopy).
Again, we presumed that a solution-state conformation
may be more biologically relevant than the corresponding
solid-state conformation seen in the X-ray structure. In two
NMR studies, (CD2Cl2 and CD3OD), there was no evi-
dence of a predominant F2F interaction.
Given the earlier agreement of experimental and theo-
retical methods as to the dominance of the F2F motif in
solution (and crystal forms) we did not anticipate this finding
especially since the data for the macrocycle (compound 3)
supported our hypothesis of the F2F motif. Our fall-back
assumption had to be that in modifying earlier compounds
the preferred conformation in solution shifted from F2F to
extended, but that to continue to be efficacious the bound
molecule reverted to the F2F form. Without a co-crystal
structure of suvorexant bound to OX1R or OX2R we cannot
substantiate this hypothesis. However, this would be unli-
kely if the energy difference between these two forms in
solution was large. As such we examined the energetics of
each in some detail (Table 4). At the time of writing this
manuscript a new version of OPLS became available (OPLS
2.1) and we found that results obtained with this newer
version were in agreement with the quantum mechanical
studies whereas OPLS 2005 was not.
It is readily apparent that the OPLS 2005 method, which
was used in our original diazepane designs, identified the
extended conformation within 1.1 kcal/mol of the global
minimum. However, the extended conformation was pre-
dominant when the MMFFs and OPLS 2.1 force fields
were utilized and continued to be predominant when
implicit solvent was included in the calculation. Coinci-
dentally, both quantum mechanical methods RHF/6-31G**
and the MMFFs and OPLS 2.1 methods were in agreement.
Irrespective, the energetic differences between the F2F and
extended conformations are quite modest suggesting that
multiple conformations of suvorexant are energetically
possible.
Although numerous computational tools, theories and
concepts can be utilized to rationalize an experimental result,
it is typically most satisfying to have experimental data to
support an outcome. Thus, we turned our analysis to Merck’s
in-house small-molecule and complexed crystallographic
data to help understand the differing suvorexant results. We
searched for small molecules where crystal structures of both
the unbound and bound forms were experimentally deter-
mined. We then calculated the RMSD between the non-
hydrogen atoms of the ligand in both structures. To ensure we
were not biasing towards molecules with low molecular
weight (and thus, likely to have relatively fewer rotatable
Fig. 4 X-Ray structure of Suvorexant (MK-4305/Compound 7)
Table 4 Energetic differences between the extended and F2F shape
motif of Suvorexant using different levels of theory
Compound 7 F2Fa Extendeda
OPLS (2005) gas 0.0 1.1
OPLS (2005) solvent 0.0 1.1
OPLS (2.1) gas 1.1 0.0
OPLS (2.1) solvent 0.15 0.0
MMFFs gas 1.4 0.0
MMFFs solvent 0.62 0.0
RHF/6-31G** gas 2.7 0.0
RHF/6-31G** PBF 1.7 0.0
a Energies are in kcal/mol and the lowest energy structure is nor-
malized to zero
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bonds), we examined 17 compounds from our in-house
crystallography database over a range of molecular weight
values. As is demonstrated in Fig. 5, there is often a differ-
ence between the bound and unbound ligand conformations.
In fact, Merck’s drug for the treatment of diabetes (Januvia)
shows a marked difference between the bound and unbound
crystal structures (Fig. 5) [16].
The literature also suggests that while the predicted low
energy solvated structure is often the bioactive this is not
always true [17, 18] (Fig. 6).
Up to this point, we had developed our F2F hypothesis based
on the solvation-corrected force field relative energies,
assuming that these enthalpic contributions to the overall bio-
active conformation would approximate the free energy of
binding (i.e. DH = DG), excluding any entropic contributions.
We had completely omitted the possibility that perhaps the free
energy would be more indicative of the solution state confor-
mation than examination of the relative energy. As a result, we
sought to incorporate the vibrational and rotational entropic
contributions to the free energy using implicit solvent.
Relative energies versus free energies
Conformer free energies, defined here to mean the energy
required to select one conformer from the ensemble of all
conformers in solution, were computed for compounds 1 and
7. A high-resolution conformer database was generated using
OMEGA [12] followed by energy minimization (including
Sheffield solvation [19]), followed by Poisson-Boltzmann
single-points for improved solvation estimates. Conformer
free energies were computed based on the partition function Q






Qi ¼ qivqireEirel=RT ð2Þ
and for each conformer i:
Erel ¼ EFF þ Esolv  Emin ð3Þ
The vibrational partition functions qv were calculated
using analytic second derivatives (including Sheffield sol-
vation) at each minimum [19]; the rotational partition
function qr were calculated based on moments of inertia.
Translational entropy was ignored because it cancels
between conformers. For each minimized conformer the
force field energy EFF and the solvation energy Esolv are
summed and the global energy minimum Emin is subtracted
to yield the relative energy. The conformer free energy for
conformer i is then given by:
DGi ¼ RTðlnðQiÞ  lnðQÞÞ ð4Þ
Figure 7 shows that the conformer free energies for 1
differ substantially from the relative energies; while the
global relative energy minimum conformation (F2F) shown
in Fig. 1 has one of the lowest conformer free energies,
there are extended conformers with comparably low free
energies. Allowing for inaccuracies in the force field and
for the solvation differences between water and CD3OD,
we think this is consistent with the 82 % prevalence of F2F
conformers in the NMR experiment mentioned earlier.
Compound 7 exhibits a markedly different free energy
distribution of F2F versus extended conformers as shown
in Fig. 8. Now most of the lowest free energy conformers
are all extended, with the crystal structure conformer
among them. This also explains why the solution NMR
structure reflects an extended conformation. Nevertheless,
a F2F conformer is still found amongst this cluster having
the lowest free energy and other F2F conformers are found
a couple of kcal/mol higher in free energy. Thus it is
apparent that for compound 7, while the F2F conformations
postulated for biological activity are not prevalent, they are

















Fig. 5 RMSD between the non-hydrogen atoms of the same com-
pound in the bound (complex) and unbound (no complex) crystal
structure as a function of molecular weight. The value for Januvia is
circled in red
Fig. 6 Small-molecule crystal structure colored in orange (carbon
atoms) of Januvia superposed with bound crystal structure of
Januvia colored in yellow (carbon atoms) complexed in DPPIV
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to adopt the F2F conformation is low and so could be easily
compensated for by binding free energy.
Rationalizing suvorexant’s 3D motif
Although we don’t yet have the unequivocal answer for
how suvorexant binds, the differing results between theory
and experiment can be rationalized as follows: (1) the small
molecule X-ray structure could be influenced by crystal
packing forces (2) the NMR conformations could be a
result of solvent effects (3) the conformational analysis
results invoking different levels of theory suggest that there
are low lying energy populations readily accessible (4) an
analysis comparing the bound and unbound ligand forms
indicates that the small molecule X-ray structure does not
always correlate with the bound conformation or (5) the
simplest rationale: that we need to determine the free
energy of the compound in solution through the explicit
determination of the vibrational and rotational entropic
contributions.
While we are hopeful that advances in GPCR crystal-
lography will come to shed light on this puzzling differ-
ence, we believe this work presents a cautionary tale for
ligand-based design. If we had been unfortunate to have
started with an active molecule similar in conformation to
the unbound X-ray structure of suvorexant, we might not
have recognized the F2F motif. That said, we would have
likely challenged the F2F motif to be a possible bioactive
conformation since the F2F conformation is energetically
quite accessible as determined by multiple computational
methods. It was the application of multiple orthogonal
methods incorporating experimental tools that aided in
developing a testable hypothesis.
Conclusion
In the work presented here we follow a tight hypothesis:
that a predominantly F2F motif is the bioactive confor-
mation for active DORAs. Whether the structure of suvo-
rexant bound to OX1R and/or OX2R turns out to be
extended or not, we were successful in applying our F2F
motif hypothesis, derived from a thorough understanding
of the shape of the ligand. The important aspect of this
approach was relying on multiple orthogonal methods to
investigate the bioactive conformation. Clearly, in the
quest for a novel sleep medication, the integration of many
experimental and theoretical methods ‘‘worked’’ to refine
the hypothesis and shape based analysis helped to develop
Merck’s DORAs.
In trying to understand the experimentally determined
preference for compound 7, we found that a critical role
was played by methyl substitution on the seven membered
diazepane ring. While this introduced a marginal prefer-
ence for the extended conformation in some cases (Fig. 8),
the F2F conformation was always within a kcal/mol of the
global minimum and often preferred.2
Fig. 7 Conformer free energies versus relative energies (force
field ? solvation) for accessible conformations of 1. Blue stars
Extended conformations; green circles F2F conformations. The
model for the bioactive conformation (F2F) is outlined in red. There
are extended conformers close in free energy
Fig. 8 Conformer free energies versus relative energies (force field
and solvation) for accessible conformations of 7. Blue stars Extended
conformations; green circles F2F conformations. The minimum
corresponding to the X-ray conformation (extended) is outlined in red
2 When combined with other structural modifications, incorporation
of the 7-methyl substituent on the diazepane ring was discovered to
have an unexpectedly favorable effect on the pharmacokinetic profile.
See Ref. [10].
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The use of the partition function ensures that we have
incorporated all the important energetically accessible
energy minima including both the F2F and extended con-
formations. Secondly, by including the vibrational and
rotational entropic contributions of each conformer, we
find that these influence whether the F2F or extended
conformation are preferred within a force field—or within
the same force field potential energy surface. Irrespective,
the energy differences were within a 1 kcal/mol lending us
to conclude that both F2F and extended conformations are
significant contributors to the unbound conformational
ensemble in solvent.
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